By: Quincy Attobrah From: oncnursingnews.com Datopotamab deruxtecan (Datroway) demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in patients with previously untreated, advanced triple-negative breast cancer (TNBC) who were not eligible for immunotherapy, according to results from the phase 3 TROPION-Breast02 trial. The findings, published in Annals of Oncology, address a significant unmet need in TNBC, …
Complementary, alternative medicines associated with worse survival in breast cancer
By: Josh Friedman From: healio.com Key takeaways: Use of complementary and alternative medicines had a significant association with worse survival in breast cancer. Women who used these treatments had lower use of radiation and endocrine therapy. Women with breast cancer treated with complementary and alternative medicines have significantly worse survival than those receiving traditional therapies, likely due to underutilization of …
Is Vitamin D a Key to Better Breast Cancer Survival?
By: Ernie Mundell From: medscape.com For women with breast cancer, vitamin D levels around the time of diagnosis might be related to long-term survival, a large prospective study showed. Over a median of 12 years, women with sufficient vitamin D levels at breast cancer diagnosis had a 24% boost in overall survival compared to those with a vitamin D deficiency, …
Better Survival, Cardiometabolic Outcomes in Breast Cancer Patients With Sufficient Vitamin D Levels
Women with breast cancer who have sufficient vitamin D levels have improved survival outcomes compared to those with vitamin D deficiency, according to research published in the Journal of the National Comprehensive Cancer Network. Patients with sufficient levels of vitamin D also have a lower incidence of cardiometabolic risk factors than those without sufficient levels, study researchers reported. In this …
Alternative Treatments are Linked to Lower Breast Cancer Survival
By: Stacy Kish From: yale.edu Advances in early screening mammography and new, targeted treatments have reduced overall mortality and recurrence in breast cancer. Yet, despite these advances in traditional treatment options, some patients continue to choose complementary and alternative medicine (CAM), such as dietary supplements, mind and body approaches, and acupuncture. “I was moved by a patient discussing her decision …
MONALEESA Trial: The Study That Quietly Rewrote Survival in HR-Positive Metastatic Breast Cancer
By Armen Gevorgyan, MD From: oncodaily.com For years, hormone receptor–positive (HR+) metastatic breast cancer was described as “indolent.” It wasn’t. It was slower than triple-negative disease. It was more responsive to endocrine therapy. But resistance was inevitable. Median overall survival rarely crossed four years in metastatic settings. Treatment sequencing revolved around endocrine therapy first, chemotherapy later. Then came the MONALEESA …
ACS reports milestone increases in cancer survival
By: Amerigo Allegretto From: auntminnie.com Cancer mortality rates continue to decline, with five-year survival rates reaching milestones, according to the American Cancer Society’s (ACS) annual cancer statistics report released on January 13. The ACS reported that about seven in 10 people who were diagnosed with cancer are reaching the five-year survival milestone, up from less than half of people in …
Overall Survival Increasing in Advanced Breast Cancer
Source: HealthDay News From: oncologynurseadvisor.com Increase seen in overall survival, especially among those with HER2+-positive cancers, with median increase of more than 10 months. For women with advanced breast cancer (ABC), overall survival is increasing, especially among those with human epidermal growth factor receptor 2 (HER2)-positive cancers, according to a study presented at the Advanced Breast Cancer Eighth International Consensus …
Sac-TMT Yields PFS Benefit Over Chemotherapy in Pretreated HR+, HER2– Metastatic Breast Cancer
By: Andrea Eleazar, MHS From: onclive.com Key Takeaways Sacituzumab tirumotecan significantly improved progression-free survival compared to chemotherapy in HR+/HER2– breast cancer, reducing disease progression or death risk by 65%. The median progression-free survival for sac-TMT was 8.3 months, nearly double that of chemotherapy, with consistent benefits across subgroups. The safety profile of sac-TMT was manageable, with hematologic toxicities being the …
Abemaciclib Ups Overall Survival in High-Risk Breast Cancer
By: Liam Davenport From: medscape.com TOPLINE: Patients with hormone receptor positive (HR+), HER2-negative (HER2-), high-risk early breast cancer experience a significant overall survival benefit with the addition of the CDK4/6 inhibitor abemaciclib to endocrine therapy, as well as a reduction in rates of metastatic disease, according to an analysis of data from the monarchE trial presented at the ESMO Congress …